Prasugrel (Efient®)

Assessment Status Assessment Process Complete
HTA ID -
Drug Prasugrel
Brand Efient®
Indication For the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing primary or delayed percutaneous coronary intervention.
Assessment Process
Full submission received from Applicant 31/07/2009
NCPE assessment completed 01/02/2010
NCPE assessment outcome Reimbursement Recommended

Technical Summary

The review group consider that prasugrel, co-administered with aspirin, is cost-effective in patients with acute coronary syndrome undergoing primary or delayed percutaneous coronary intervention in the Irish healthcare setting.